As digital health technologies (DHTs), wearables, and decentralized clinical trial models become standard in modern drug and device development, digitally-derived endpoints offer unprecedented continuous monitoring capabilities. However, continuous data collection brings a critical challenge: missing data.

In the high-stakes world of clinical trials, there is a pervasive misconception among executives that "more sites" and "big-name institutions" are the silver bullets for meeting enrollment deadlines. The logic seems sound: partner with a subject matter expert at a world-renowned hospital to gain instant credibility and access to vast patient pools.